Generic Drugs Market In Malaysia

Generic drugs market in Malaysia

It is important that the large multinational pharmaceutical companies have forgotten to set drug prices in the country. 

Malaysia has a pharmaceutical manufacturing sector that produces almost exclusively generic drugs, and whose sales revenues amount to only 1.5% of gross domestic product (GDP). 

The five largest companies typically sell originator drugs and account for 47 percent of total drug imports. The average cost of importing a generic drug in Malaysia ($1,000 to $2,500) is 87 percent higher than revenue.

The government is the largest pharmaceutical buyer in Malaysia and is responsible for more than half of the pharmaceutical purchasing value [this post gives more details about buying meds and choosing healthcare options in Malaysia]. 

While local manufacturers can produce medicines in all categories of medicines that are on the list of essential medicines, imports, especially high-quality medicines, are necessary to meet domestic demand. 

Malaysian manufacturers are now beginning to increase their investment in research and development and produce higher value-added products - products with added value, such as pharmaceuticals, medical devices, and medical devices.
 
The rest of the market is divided between private clinics, private clinics, and pharmacies. Because the public health system's job is to provide the needy with medicines at near-zero cost, it avoids end-sales - that is, price increases (here's a quick look into generic medicines franchises)
 
Pharmaceutical experts spoke about four aspects that generic manufacturers must take into account when purchasing active pharmaceutical ingredients, such as cost, quality, availability, quality control, and safety.
 
According to Zion Market Research, the global generic market is growing at more than 10 percent per year and is expected to reach approximately $380 billion by 2021. This growth is reflected in improved public health and lower prices for consumers, as well as higher sales of generic medicines.
 
To summarize briefly: a generic is a brand name medicine with a specific purpose, such as to treat a disease or medical condition.
 
Nevertheless, the problems related to pharmaceutical patents continue to pose a challenge for Malaysia.

In this article, we examine the market for generic medicines in the Malaysian market, following the introduction of the first generic patent in 2010 and the introduction of generic patent law in 2012. The paper was presented at the International Conference on Pharmaceutical Research and Development (IPRDC) in Kuala Lumpur, Malaysia, in June 2017.
 
Indian generic drug manufacturers have also begun to play a dominant role in the Malaysian market, following the accelerated approval process agreed by the governments of the two countries. 

The companies have stepped up their efforts to get their generic medicines approved by regulators after deciding to build new production facilities in both countries and use Singapore as a launchpad for Southeast Asia. 

This study started after an analysis of guidelines, focusing on the market for generic medicines in Malaysia and the impact of changes to the generic.
 
B - Research cited the example of Beacons Pharmaceuticals, which is privately owned and produces its own range of generic drugs and offers contract manufacturing and packaging services. 

BMI Research said it focuses mainly on generic and dietary supplement products and that it produces its own ranges of generic drugs and contracts for manufacturing, packaging, and services to other generic manufacturers in Malaysia and other parts of Asia.
 
In developing countries, citizens can usually trust that the medicines on pharmacy shelves are safe, authentic, and effective. 

However, they face increasing competition from foreign generic drug suppliers, which have established themselves in the market for public tenders. Indian and Chinese companies that produce high-quality generic medicines and export them around the world are competing.
 
Most families and doctors will probably opt for quality - guaranteed generics that are tested for bioequivalence, systematically tested for side effects, manufactured, and marketed well - in comparison to brand-name competitors.
 
For example, non-branded generics account for more than 40% of the total US pharmaceutical market in the United States and more than 50% in the United States, the United States, and the United Kingdom. 

The Malaysian health system is crucial to this system, especially in the face of rising costs and the prevailing economic crisis.
 
Trade-related aspects of the generic market in Malaysia, such as prices, availability, quality, and availability of generic medicines and market access.
 
Malaysia's 32 million people currently spend an average of $375 per year on health care, about 75% of which is spent on medicines. There are no patented antiretroviral products that could be sold on the generic market in Malaysia. As a result of these licenses, the number of HIV-infected patients who have access to generic medicines has fallen by 83%.

However, measures have been taken to increase the availability of generics in high-priced patented forms, such as the introduction of a generic version of the anti-HIV drug nivolumab. These are expensive and cause serious health problems for patients and their families.
 
As per capita income rises, Malaysians spend more disposable income on pharmaceuticals. Foreign pharmaceutical companies' products are not usually manufactured in Malaysia, and most brand-name drugs such as antiretroviral and cancer drugs are sold in the United States, Canada, Australia, New Zealand, and other countries.

Popular Generic Drugs In Malaysia


A total of 154 generic drugs were among the top 10 best-selling prescription drugs in Malaysia. The majority of respondents were dissatisfied with the quality of generics understood and administered by healthcare professionals. Respondents judged government policies and regulations to be insufficient to promote generic drugs in Malaysia.
 
A high proportion of the samples were for the cardiovascular class, followed by respiratory and nervous system drugs, reflecting the burden of disease on the Malaysian population. The report also found that there is strong competition in this category of medicines studied, both for innovation brands and generic medicines.

 
The problem is the extent to which the market is allowed to determine the prices of medicines. Although Malaysia does not control the price of medicines, market failure is expected if the information available is coupled with monopolies and patent protection by the pharmaceutical industry. 

The Malaysian government has encouraged the pharmaceutical industry to grow, and Malaysia practices a free market in drug prices.

Yet the growing burden of disease on the Malaysian population, especially in the respiratory system, cannot be ignored. Expensive medicines can no longer be dismissed as a problem of inappropriate prescribing, especially when prescriptions in the retail, generic, and private sectors cost up to 10-20% of the cost of prescription medicines.
 
Malaysia's procurement authorities must use such evidence effectively in their decision-making. The system of differential pricing should be recognized as a serious threat to the quality of life of the public health system.
 
Public involvement in drug pricing is necessary because the financing and supply of medicines can be left entirely to the market economy in order to achieve public health objectives. For example, in the case of patented Sofosbuvir, the state use of licenses is necessary to break up monopolies and allow the sale of generic medicines at affordable prices.
 
In other words, the Malaysian government has granted US companies patents for Sofosbuvir to protect the patent. In return, Malaysia reserves the right to use the patented invention for the benefit of the public.
 
According to the Geneva-based initiative DNDi (Drugs for Neglected Diseases), the Malaysian Ministry of Health hopes to obtain a generic drug, sofosbuvir, for 1,000 RM. It is crucial for the Malaysian health system, given the rising cost of medicines and the prevailing economic crisis.
 
As a result of the license, the number of HIV-infected patients in the country's public health system has fallen by 83%. There are no patented antiretroviral products on sale in Malaysia, and the patented forms are very expensive. 

Trade-related aspects: what measures can be taken to increase the price of these medicines, especially those patented?
 
These are medicines for the treatment of asthma and chronic obstructive pulmonary disease. The five countries with the cheapest drugs are Brunei Darussalam, Malaysia, Indonesia, Singapore, Thailand, and the United States, with branded drugs at an average price of $2,000.

For certain medicines, Malaysia charges patients more than other countries in the region, such as the US and Australia, because they rank higher on Malaysia's list of the ten most expensive medicines. 
The Medbelle price index showed that drugs were cheaper in Thailand, Kenya, and Malaysia, but the US topped the list of the most expensive drugs.

Australia fared worst with drugs that lower cholesterol, such as cholesterol-lowering drug Lipitor, the second most commonly prescribed drug in the country. The price of life-saving lung cancer and leukemia drugs has been cut following the Government's decision to include new drugs in the drug benefit system.

Following the publication last year of a report by the Malaysian Institute of Public Health (MIPH), we are examining the impact of patent protection on the availability and access to generic medicines in the country. 

"We are strict in the definition of patents," he said, stressing that Malaysia should seriously consider these criteria for patent protection. Leonard believes there are useful lessons to be learned from the country's growing generic drug industry, which the Department of Chemistry and Pharmaceuticals has in identifying problems affecting the country's pharmaceutical industry.

Leonard says price controls are ineffective in keeping drug prices affordable because it is difficult to manage 20,000 medicines in Malaysia. He said that if it was not helpful for companies to recoup their cost investments, they could decide not to import drugs into the countries, as there would be a loss of patients.
 
Nevertheless, the problems related to pharmaceutical patents continue to pose a challenge to the availability of medicines and generics in Malaysia. The work was presented at the annual meeting of the International Association for the Advancement of Science in Medicine (IASM) on Tuesday, 14 March 2017 in Kuala Lumpur, Malaysia.

No comments:

Post a Comment